The Study of Trilaciclib Combined With Chemotherapy On The Neoadjuvant Therapy of TNBC

Trilaciclib indication: Trilaciclib, a CDK4/6 inhibitor, was used before chemotherapy to reduce the incidence of bone marrow suppression and approved by the FDA for small cell lung cancer patients in 2021.